EMERYVILLE, Calif. (March 19, 2020) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report 2019 fourth quarter and full year financial results after market close on Thursday, March 26, 2020 and will hold an investment community conference call that day.
DATE: Thursday, March 26
TIME: 4:30 p.m. ET / 1:30 p.m. PT
DIAL IN: 800-608-8202 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 5299253
The live call also will be available at https://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time April 13, 2020, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 5299253. The call will also be archived at https://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, CELLERX® for the aesthetic dermatology market and NEUTROPHASE® for the wound care market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
President and Chief Executive Officer
LHA Investor Relations